pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 Lilly is thought to be the first pharma company to sign up to use the new camptothecin payload platform.

Antibody 52

Antibody Licensing Licensing Drugs 52

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC). billion upfront, when it licensed the ADC from Daiichi Sankyo in 2019.

Sales 54

Sales Antibody Drugs Pharma Companies 54

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

Delveinsight

AUGUST 2, 2020

The company has also signed a licensing agreement with Ono Pharmaceutical , a Japanese pharma company, transferring exclusive rights to develop and commercialise anamorelin in Japan, South Korea, and Taiwan. Cancer Cachexia Pipeline. Apart from the products as mentioned earlier, Tetra Bio?Pharma,

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

SEPTEMBER 8, 2022

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies. This is why the recent surge in development for radiopharmaceuticals is drawing attention. Aktis has taken a different approach.

Manufacturing 105

Manufacturing Development Antibody Drugs 105

Drug Discovery World

OCTOBER 16, 2023

Cambridge boasts the world-renowned university alongside a biotech and pharma cluster situated throughout the city and its surrounding science parks, all of which helps attract top scientific talent.” At ELRIG’s Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provided a snapshot of drug discovery in Scotland.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

DECEMBER 21, 2020

The agreement sees San Diego-based Janux in line for around $500 million in milestones apiece for two T-cell engager therapies – which bind to a tumour cell and recruit a patient’s T cells to eradicate tumour cells – that will be developed using Janux’ TRACTr platform. Other recent deals include a $2.8

Immune Response 54

Immune Response Sales Antibody Pharma Companies 54

Drug Discovery World

JULY 2, 2024

Basel is probably Switzerland’s most developed hub, though there is significant investment in other cities like Lausanne, Zurich and Geneva. So, in this way there is a cross fertilisation from the bigger companies to newer ones. For example, biotechs Actelion and Light Chain Bioscience/Novimmune were both started by Roche scientists.

Life Science 59

Life Science Drugs Development Research 59

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Several of the large pharma companies have recently re-entered the dementia field.

Development 52

Development In-Vivo Compound Screening Clinical Development 52

Drug Discovery World

JULY 22, 2024

In addition to BSB-1001, BlueSphere has also discovered and nominated three additional miHA-targeting TCRs for clinical development, all for use in the same clinical setting as BSB-1001. Currently, there are several of companies that hope to bring the potential of TCR-Ts to patients that have not yet benefited from other cell therapies.

Gene Therapy 52

Gene Therapy Engineer Manufacturing Gene 52

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

JANUARY 7, 2021

The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.

Doctors 53

Doctors Doctor Immune Response Pharma Companies 53

pharmaphorum

DECEMBER 21, 2020

The body produces antibodies against the protein, which neutralise the virus in the event of an infection. But both drew on the mRNA technology developed by Katalin Kariko from the University of Pennsylvania and her collaborator Drew Weissman, an immunologist from Boston University.

Vaccination 97

Vaccination Vaccine Doctors Doctor 97

pharmaphorum

MAY 14, 2021

This and its smaller size – it’s a “nanobody” that is only a fraction of the size of conventional antibodies – could allow it to penetrate deeper into the skin and joints. Licensed in from Ablynx in 2013 five years before a merger with Sanofi, German Merck recognised its potential.

Licensing 61

Licensing Licensing Drugs Marketing 61

Delveinsight

AUGUST 13, 2020

The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size. Takeda acquired an exclusive global license for CNP-101 from Cour Pharmaceuticals’in October 2019.

Marketing 52

Marketing Trials Antibody Pharma Companies 52

pharmaphorum

JANUARY 29, 2021

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.

Licensing 52

Licensing Licensing Bioavailability Antibody 52

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The drug is also being tested in other trials, including a phase 3 study looking at its role in prevention of SARS-CoV-2 infection.

Drugs 102

Drugs Antibody FDA Approval Pharma Companies 102

pharmaphorum

NOVEMBER 12, 2020

The mid-sized pharma group has also signed a collaboration with Florida, US-based Lacerta Therapeutics , adding more AAV capsids – well established as a staple for delivering gene therapy sequences – as well as another gene therapy candidate.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Drug Discovery World

OCTOBER 7, 2022

RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. HR : We want to streamline the drug discovery and development process for our industry partners. Tony Hickson.

HR 52

HR Research Drugs Development 52

The Pharma Data

DECEMBER 16, 2020

AstraZeneca has seen a few setbacks with the COVID-19 vaccine it has developed with Oxford University, including a confusing efficacy outcome that resulted from the inclusion of a half-dose. Despite those setbacks, the company anticipates its vaccine could be available for use in the United Kingdom within the next several weeks.

Vaccination 52

Vaccination Vaccine DNA Antibody 52